S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
3 Recession-Proof Dividend Stocks to Buy Now
MarketBeat Week in Review 1/11 - 1/15
Ralph Lauren drops Justin Thomas after gay slur heard on TV
The Latest: Mexico hits another record for COVID-19 cases
pixel
The Latest: Oregon governor blames feds for vaccine delay
The Latest: Spain confident of vaccine program despite delay
Bowl games look to future after weathering challenging year
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
3 Recession-Proof Dividend Stocks to Buy Now
MarketBeat Week in Review 1/11 - 1/15
Ralph Lauren drops Justin Thomas after gay slur heard on TV
The Latest: Mexico hits another record for COVID-19 cases
pixel
The Latest: Oregon governor blames feds for vaccine delay
The Latest: Spain confident of vaccine program despite delay
Bowl games look to future after weathering challenging year
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
3 Recession-Proof Dividend Stocks to Buy Now
MarketBeat Week in Review 1/11 - 1/15
Ralph Lauren drops Justin Thomas after gay slur heard on TV
The Latest: Mexico hits another record for COVID-19 cases
pixel
The Latest: Oregon governor blames feds for vaccine delay
The Latest: Spain confident of vaccine program despite delay
Bowl games look to future after weathering challenging year
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
3 Recession-Proof Dividend Stocks to Buy Now
MarketBeat Week in Review 1/11 - 1/15
Ralph Lauren drops Justin Thomas after gay slur heard on TV
The Latest: Mexico hits another record for COVID-19 cases
pixel
The Latest: Oregon governor blames feds for vaccine delay
The Latest: Spain confident of vaccine program despite delay
Bowl games look to future after weathering challenging year
pixel
Log in
OTCMKTS:CBBT

Cerebain Biotech Stock Forecast, Price & News

$0.12
0.00 (0.00 %)
(As of 01/15/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.11
Now: $0.12▼
$0.13
50-Day Range
$0.02
MA: $0.05▼
$0.12
52-Week Range
$0.00
Now: $0.12▼
$0.13
Volume21.81 million shs
Average Volume19.45 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Cerebain Biotech Corp., a biomedical company, focuses on the discovery of products for the treatment of Alzheimer's disease. Its products would include medical device solutions, as well as synthetic drug solutions. The company was formerly known as Discount Dental Materials, Inc. and changed its name to Cerebain Biotech Corp. in June 2014. Cerebain Biotech Corp. was incorporated in 2007 and is headquartered in Costa Mesa, California.

MarketRank™

Overall MarketRank™

0.00 out of 5 stars

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:CBBT
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.cerebain.com
Phone714-371-4109
Employees2

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Outstanding SharesN/A
Market CapN/A
Next Earnings DateN/A
OptionableNot Optionable
$0.12
0.00 (0.00 %)
(As of 01/15/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CBBT News and Ratings via Email

Sign-up to receive the latest news and ratings for CBBT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Cerebain Biotech (OTCMKTS:CBBT) Frequently Asked Questions

What stocks does MarketBeat like better than Cerebain Biotech?

Wall Street analysts have given Cerebain Biotech a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Cerebain Biotech wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Cerebain Biotech?

Cerebain Biotech saw a decline in short interest in December. As of December 31st, there was short interest totaling 34,500 shares, a decline of 64.4% from the December 15th total of 97,000 shares. Based on an average trading volume of 34,372,600 shares, the days-to-cover ratio is presently 0.0 days.
View Cerebain Biotech's Short Interest.

Who are some of Cerebain Biotech's key competitors?

Some companies that are related to Cerebain Biotech include (CHV) (CHV), (DDXS) (DDXS), (PREV) (PREV), (TNGN) (TNGN), 138267 (COM.TO) (COM), 17031 (MYM), Abattis Bioceuticals (ATTBF), Abzena plc (ABZA.L) (ABZA), Acrux Limited (ACR.AX) (ACR), Actinogen Medical Limited (ACW.AX) (ACW), AdAlta Limited (1AD.AX) (1AD), ADiTx Therapeutics (ADTX), Admedus (AHZ), Alaric (HALB) and Algernon Pharmaceuticals (AGNPF).
View all of CBBT's competitors.

Who are Cerebain Biotech's key executives?

Cerebain Biotech's management team includes the following people:
  • Mr. Eric Andre Clemons, Pres, CEO & Director (Age 49, Pay $231.93k)

What is Cerebain Biotech's stock symbol?

Cerebain Biotech trades on the OTCMKTS under the ticker symbol "CBBT."

How do I buy shares of Cerebain Biotech?

Shares of CBBT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cerebain Biotech's stock price today?

One share of CBBT stock can currently be purchased for approximately $0.12.

What is Cerebain Biotech's official website?

The official website for Cerebain Biotech is www.cerebain.com.

How can I contact Cerebain Biotech?

The company can be reached via phone at 714-371-4109.

This page was last updated on 1/16/2021 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.